Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History

Nuvo Research Inc T.NRI

Sector: Healthcare | Sub-Sector: Drug Manufacturers - Specialty & Generic
Alternate Symbol(s):  NRIFF | NRIFD

Nuvo Research, Inc. is a Canadian specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units: the Topical Products and Technology (TPT) Group (formerly the Pain Group) and the Immunology Group.
Price: $5.35 | Change: +$0.48 | %Change: +9.86%
Volume: 314,265 | Day High/Low: 5.70/4.96 | 52 Week High/Low: 5.73/1.58
View modes: 
5 stars

Nuvo's Amended Compliant Against Mallincrkrodt

Nuvo's Amended complaint against Mallinckrodt has been posted on their website. Interesting read. http://www.nuvoresearch.com/index.php/mallinckrodt-litigation  rate and reply
3 stars

RE:RE:RE:RE:RE:Slow and Steady

The current climb in price sure looks like it has some strength behind it simply because of the large buys that we have been witness to. With nothing recently important in the news department for Nuvo...read more
0 stars

RE:RE:RE:no discussion between NRI and MNK.....

My guest is that MNK will engage in the trial for many reason: 1- Even if the trial has started, it's always time to offer an agreement to other party 2- The element and proof presented by NRI will...read more
5 stars

RE:RE:RE:RE:Slow and Steady

Once again Nuvo is close to a breakout, this time to the upside. No guarantees but if it does break through $3 the intermediate target range is $3.70 to 3.80 The volume has been above average the...read more
1 star

RE:RE:RE:no discussion between NRI and MNK.....

I was just taking a poke at management... but I suppose they could still sell more shores if they had to.  rate and reply
5 stars

RE:RE:no discussion between NRI and MNK.....

If however, revenues suddenly arrived or product approvals were generated, they might think about being a little more conciliatory. I am not sure I understand what you mean by the statement. Revenues...read more
1 star

RE:no discussion between NRI and MNK.....

MNK may find the best solution is to stall and wait for Nuvo to spend all of its money paying for a bloated management team. If however, revenues suddenly arrived or product approvals were generated,...read more
5 stars

RE:no discussion between NRI and MNK.....

The court case will be decided on its merits and if MNK decides they can't win they will seek for a settlement. That said if there is a lot of money at stake they could simply delay making the...read more
5 stars

RE:RE:RE:Slow and Steady

I am guardly optimistic that $2.50 support has held again! Yesterday was a very impressive test with high volume with today a little more follow through. Onwards to the next test of $3.00 resistance...read more
0 stars

RE:large forward Tax Loss assets

Which is basically my point about Nuvo - it has more value to shareholders "dead than alive". Nuvo can not generate positive cash flow and therefore can not sustain itself without selling assets...read more
2 stars

RE:RE:large forward Tax Loss assets

Another of the Lil Folk has spoken. We genuflect..  rate and reply
2 stars

RE:large forward Tax Loss assets

I seriously doubt that Nuvo will ever get to use any of the accumulated US or Canadian tax losses but I think that they are very capable of increasing these amounts in a slow and steady manner as we...read more
0 stars

no discussion between NRI and MNK.....

Regarding NRI just amended their complaint against MNK, could we admit there's no discussion between them, so we'll not about to see a agrement or settelment in 2014.........???  rate and reply
2.5 stars

large forward Tax Loss assets

Not recognized in the Asset base are very attractive forward non capital and capital tax loss pools. These include over $47 million US in non capital tax loss carry forwards . The...read more
0 stars

Interesting from Yahoo Finance

Interesting point in this article........ http://finance.yahoo.com/news/t-nri-nriff-nuvo-q2-130000440.html  rate and reply
5 stars

RE:RE:Comments re: Nuvo Q2 Financials

If I were to look at this via a comprehensive strategy to pad ones pockets I would say the lawsuit is a great tool to prop up the stock price. This allows for dilution and pocket padding with a...read more
3.5 stars

RE:Comments re: Nuvo Q2 Financials

Well, I see things are still not loking rosy since I left. C99, I agree with your analysis, but don't think that the settling of the lawsuit will result in any additional money in shareholder value...read more
4 stars

Comments re: Nuvo Q2 Financials

The accumulated deficit as of June 30 2014 was $(236.6) million. The Q2 2014 loss of $(2.3) million was marginally worse than the $(2.2) million loss in Q2 2013. The Company expects that it will...read more
3 stars

RE:Q2..Steady as She Goes

The Third quarter should be another record quarter. 18000 prescriptions of Pennsaid 2 in Q2 compared to 6,000 prescriptions in the first quarter of 2014. Despite a drop in Pennsaid prescriptions  to...read more
2.5 stars

Q2..Steady as She Goes

Another solid quarter, with transistional sales of P2 now outperforming the expected decline in P1 sales, leading to a 15 % increase in overall sales relative to 2013. Cash burn is less than $2 per...read more